KOWLOON

NCI Announces Game-Changing Acquisition Turbocharges Retail Expansion

Retrieved on: 
星期三, 五月 29, 2024
Name, Intellectual property, Seemabaddha, NCI, Holding, Acquisition, CFO

HONG KONG, May 29, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced a game-changing acquisition.

Key Points: 
  • HONG KONG, May 29, 2024 (GLOBE NEWSWIRE) -- Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced a game-changing acquisition.
  • Under the deal, NCI will take full ownership of the highly-valuable "Les100Ciels" and "SIU" brands, including all associated trademarks and trade names.
  • "This strategic move turbocharges our retail expansion, especially in the booming Middle East markets," declared Miss Eva Siu, Chairlady and CEO of NCI.
  • It's a game-changer that will maximize shareholder value as we scale up our retail footprint worldwide."

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

Retrieved on: 
星期五, 五月 24, 2024
Patient, Tislelizumab, Survival, Osteosarcoma, Liver, HER2, Colorectal cancer, SOX, Safety, Sarcoma, Neoadjuvant therapy, University Challenge 2013–14, Trial of the century, PD-1, LARC, FRU, CAPOX, Capecitabine, Sintilimab, MSS, Pharmaceutical industry

Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single-arm, prospective phase II trial (RIFLE)

Key Points: 
  • Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single-arm, prospective phase II trial (RIFLE)
    A propensity score matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: real-world data
    Efficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter study
    A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic arteryinfusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival
    Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial
    Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): a multicenter, single-arm, open-label, phase II study
    Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study
    Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: updated results of a multicenter, single-arm, phase 2 trial
    Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multi-centered retrospective study
    Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study
    Surufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): an open-Label, single-Arm, phase II Study
    Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy: updated analysis

Neo-Concept International Group Holdings Limited Announces Collaboration with Reiss Limited

Retrieved on: 
星期三, 五月 22, 2024
City, Collection, Sale, Reiss, NCUK, Collaboration, NCI

HONG KONG, May 22, 2024 (GLOBE NEWSWIRE) --  Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced that its wholly-owned subsidiary Neo-Concept UK Limited (“NCUK”) had entered into a framework collaboration agreement (the "Collaboration Agreement") with Reiss Limited (“REISS”) to produce a range of co-branded “REISS x Les100Ciels” products.

Key Points: 
  • HONG KONG, May 22, 2024 (GLOBE NEWSWIRE) --  Neo-Concept International Group Holdings Limited (Nasdaq: NCI) (the “Company”), a one-stop apparel solution services provider, today announced that its wholly-owned subsidiary Neo-Concept UK Limited (“NCUK”) had entered into a framework collaboration agreement (the "Collaboration Agreement") with Reiss Limited (“REISS”) to produce a range of co-branded “REISS x Les100Ciels” products.
  • The products will be exclusive to this collaboration and will be sold through NCUK 's online ( www.les100ciels.com ) and retail channels, as well as distributed to REISS for sale through its retail network.
  • "We are thrilled to be partnering with Reiss on this exciting new collaboration," said Eva Siu, Chairlady of NCI.
  • The first products from the " REISS x Les100Ciels " collection are expected to be available for purchase in Q4 2024.

NCI Announces Expansion Plan of UAE and GCC Retail Markets through Signing of MOU with Retail Operator Liwa Trading Enterprises LLC to Establish Joint Venture

Retrieved on: 
星期二, 五月 21, 2024
Partnership, Liwa, JV, GCC, Gulf Cooperation Council, NCI, Food delivery

The joint venture will leverage the complementary strengths of NCI and Liwa to expand the reach of apparel products and services in the UAE and wider Gulf Cooperation Council (GCC) region, including Saudi Arabia, Kuwait, Bahrain, Qatar, and Oman.

Key Points: 
  • The joint venture will leverage the complementary strengths of NCI and Liwa to expand the reach of apparel products and services in the UAE and wider Gulf Cooperation Council (GCC) region, including Saudi Arabia, Kuwait, Bahrain, Qatar, and Oman.
  • The JV will focus on retail, wholesale, distribution, and e-commerce operations, bringing together NCI's design and supply chain expertise with Liwa's extensive regional market knowledge and established distribution network.
  • "By partnering with their respected team, we see tremendous opportunities to deliver innovative apparel offerings and enhance the shopping experience for customers across the GCC."
  • “The partnership with Liwa enables NCI to expand into the retail markets of UAE and GCC region, where we see demand for our products is increasing exponentially.

SmallRig's Award-Winning Products from the 2024 NAB Show Continue to Capture Industry Attention

Retrieved on: 
星期二, 五月 21, 2024
Panasonic, PD, HDMI, Tripod head, Life, DJI

The NAB Show Product of the Year Awards celebrates the most promising and pioneering products and technologies showcased at the event.

Key Points: 
  • The NAB Show Product of the Year Awards celebrates the most promising and pioneering products and technologies showcased at the event.
  • This year, SmallRig's cutting-edge offerings stood out among entries from renowned brands such as Panasonic, Fujifilm, and DJI.
  • SmallRig's VB212 Mini V-Mount Battery features with its 212Wh capacity and supports PD 3.1 fast charging up to 140W.
  • In conjunction with these award-winning products, SmallRig is also proud to announce the upgrade of its brand identity.

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

Retrieved on: 
星期五, 五月 17, 2024
Security (finance), Telecommunications, Patient, HKEX, HK, Retirement, Water, Health, Stock exchange, Al-Quds, Letter, Ageing, Master of Arts, Hebrew University of Jerusalem, Cancer, Attention, Committee, Part, Government, Rotation, Biotechnology, Harvard University, Family, CK Hutchison Holdings, Management

He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water.

Key Points: 
  • He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water.
  • He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison group, which focuses on large scale desalination and hydro-electric projects.
  • We look forward to his leadership and contributions to the Company’s continued success.”
    The appointment of Dr Eldar as Chairman will take effect on May 17, 2024.
  • Such amounts are subject to review from time to time and proration for an incomplete year of service.

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

Retrieved on: 
星期五, 五月 17, 2024
Patient, European Hematology Association, ITP, HCM, Purpura

ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in adult patients with primary Immune Thrombocytopenia (“ITP”) who have received at least one prior line of standard therapy ( NCT05029635 ).

Key Points: 
  • ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in adult patients with primary Immune Thrombocytopenia (“ITP”) who have received at least one prior line of standard therapy ( NCT05029635 ).
  • The median time to response was 1.1 weeks with sovleplenib.
  • It demonstrated a tolerable safety profile with grade 3 or above treatment-emergent adverse events (TEAEs) in 25.4% of patients with sovleplenib and 24.2% with placebo.
  • Details of the presentations are as follows:
    Efficacy and Safety of The Syk Inhibitor Sovleplenib (HMPL-523) in Adult Patients with Primary Immune Thrombocytopenia in China (ESLIM-01): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study

UCLOUDLINK GROUP INC. Announces Unaudited First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 15, 2024
UCL, Viva Technology, Investment, Growth, Travel, Marketing, Software as a service, ADS, Internet of things, Depreciation, GAAP, SIM, Research, Human, ESIM, Platform as a service, OTA

HONG KONG, May 15, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced its unaudited financial results for the three months ended March 31, 2024.

Key Points: 
  • HONG KONG, May 15, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced its unaudited financial results for the three months ended March 31, 2024.
  • As a proportion of daily active terminals, 57.9% were from uCloudlink 1.0 international data connectivity services and 42.1% were from uCloudlink 2.0 local data connectivity services during the first quarter of 2024.
  • The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.
  • UCLOUDLINK will hold a conference call at 8:30 a.m. Eastern Time on Wednesday, May 15, 2024 (8:30 p.m. Beijing Time on the same day) to discuss financial results and answer questions from investors and analysts.

UCLOUDLINK GROUP INC. to Report First Quarter 2024 Financial Results on May 15, 2024

Retrieved on: 
星期三, 五月 8, 2024
UCL

HONG KONG, May 08, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024 before U.S. markets open on Wednesday, May 15, 2024.

Key Points: 
  • HONG KONG, May 08, 2024 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2024 before U.S. markets open on Wednesday, May 15, 2024.
  • Management will hold a conference call to discuss these results at 8:30 a.m. U.S. Eastern Time / 8:30 p.m. Beijing Time the same day.
  • Listeners may access the call by dialing:

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Retrieved on: 
星期三, 五月 8, 2024
Goldman Sachs, Stock exchange, University, HKEX, MBBS, Fintech, Business administration, Innovation, Postgraduate diploma, Business, Yale University, Data science, University of Hong Kong, Therapy, Ageing, Security (finance)

Dr Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors.

Key Points: 
  • Dr Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors.
  • She is an experienced board director and chair, with a healthcare and financial services background in investment banking, asset management, venture capital and compliance.
  • The Board of HUTCHMED is of the view that Dr Bhatia will further enhance the skill set, expertise and knowledge base of the Board as a whole.
  • Mr Simon To, Chairman of HUTCHMED, said “On behalf of the Board, I would like to extend a warm welcome to Dr Bhatia to the Company.